BioSpace News Archive

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended September 30, 2019 and provided a business update.

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, reported financial results for the third quarter ended September 30, 2019.

CymaBay Therapeutics, Inc. announced that management will participate in two investor conferences including the Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York City and the Evercore ISI 2nd Annual HEALTHCONx Conference in Boston, MA – December 3-5, 2019.

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2019 and provided a company update.

scPharmaceuticals Inc. announced that John Tucker, chief executive officer, will present and host investor meetings at the Jefferies 2019 London Healthcare Conference being held at the Waldorf Hilton in London, UK.

Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York, NY on Tuesday, November 19, 2019 at 3:00 p.m. ET.

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorectal and leukemia, today announced new positive data from its Phase 2 trial evaluating onvansertib in combination with Zytiga®

Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019.